Filing Details
- Accession Number:
- 0001415889-23-007139
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-05-02 20:04:29
- Reporting Period:
- 2023-04-28
- Accepted Time:
- 2023-05-02 20:04:29
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1800 | Abbott Laboratories | ABT | Pharmaceutical Preparations (2834) | 360698440 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 902132 | J Daniel Starks | 100 Abbott Park Road Abbott Park IL 60064 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares Without Par Value | Acquisiton | 2023-04-28 | 1,816 | $0.00 | 6,875,316 | No | 4 | A | Direct | |
| Common Shares Without Par Value | Disposition | 2023-05-02 | 46,548 | $110.97 | 6,828,768 | No | 4 | S | Direct | |
| Common Shares Without Par Value | Disposition | 2023-05-02 | 3,452 | $111.75 | 6,825,316 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Option (right to buy) | Acquisiton | 2023-04-28 | 8,136 | $0.00 | 8,136 | $110.12 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 8,136 | 2023-04-28 | 2033-04-27 | No | 4 | A | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Shares Without Par Value | 258 | Indirect | Alynne Starks 2012 Irrevocable Trust |
Footnotes
- These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.51 to $111.50, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.58 to $111.90, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- Held in the Alynne Starks 2012 Irrevocable Trust. The reporting person is the sole trustee of the trust.
- Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Billionaire Hedge Funds
